POZEN (POZN) Tops Q4 EPS by 4c; Updates on FDA CRL
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
POZEN Reports Fourth Quarter and Year End 2014 Results
March 9, 2015 7:30 AM EDT- Reports Annual Net Income of $19.7 Million, Including VIMOVO Royalty of $21.1 Million -
- Updates Anticipated Commercialization Timing -
CHAPEL HILL, N.C.--(BUSINESS WIRE)-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2014.
Corporate Highlights
Q4 2014 was the fourth consecutive profitable quarter and the third consecutive quarter of positive cash flow. 2014 profit was $19.7 million, compared to a 2013 loss of $(16.7) million.... More